Total
0
Shares
Imagion Biosystems (ASX:IBX) - CEO & President, Bob Proulx
CEO & President, Bob Proulx
Source: HotCopper
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Imagion Biosystems (IBX) has entered an agreement with Siemens Healthineers to explore the use of MagSense nanoparticles as an MRI contrast agent
  • Contrast agents are used to enhance the image and resolution during MRI scans — thus providing a more accurate method for detecting cancer
  • Together, the companies will identify specific protocols for using MagSense to monitor cancer through MRI scanning
  • Imagion aims to undertake its first clinical study of the MagSense technology in HER2 breast cancer patients
  • IBX is up a healthy 18.2 per cent and shares are trading for 2.6 cents each

Imagion Biosystems (IBX) has entered a collaboration agreement with Siemens Healthineers to further explore the use of Imagion’s MagSense nanoparticles.

The collaboration with Siemens, a leading medical technology company, is in line with Imagion’s strategy to develop new uses of the MagSense nanoparticles as an MRI contrast agent.

Contrast agents are used to enhance the image and improve resolution when doing MRI scans. The companies believe the MagSense nanoparticle could be used as a contrast agent to enhance an MR image of specific diseased tissue. By doing so, this will provide a more accurate method of non-invasively detecting cancer.

Together, the companies will identify specific protocols for using MagSense to monitor cancer through MRI scanning.

“The ability to use a targeted contrast agent like ours, in the MRI setting, could transform the way MRI is used to diagnose cancer and other diseases. In entering into this collaboration, we will jointly gain insight into the clinical and commercial potential of our novel technology,” Imagion Executive Chairman Bob Proulx said.

“Imagion’s targeted contrast technology, MagSense, could offer patients a more specific means to monitor cancer with MRI, and we look forward to assisting Imagion in investigating the application of their technology with MRI scanners,” Siemens Head of Collaborations and Research for Australia and New Zealand Dr Kieran O’Brien said.

Imagion Biosystems previously announced its intention to manufacture MagSense for a HER2 breast cancer study and this collaboration further establishes a pathway to commercialise the MagSense technology.

IBX is up a healthy 18.2 per cent and shares are trading for 2.6 cents each at 10:17 am AEST.

IBX by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.